The role of ultrasound guided peri-tendinous injection in the treatment of non-calcific tendinopathy  by Niazi, Gamal & Habib, Lobna
The Egyptian Journal of Radiology and Nuclear Medicine (2015) 46, 71–78Egyptian Society of Radiology and Nuclear Medicine
The Egyptian Journal of Radiology andNuclearMedicine
www.elsevier.com/locate/ejrnm
www.sciencedirect.comORIGINAL ARTICLEThe role of ultrasound guided peri-tendinous
injection in the treatment of non-calciﬁc
tendinopathy* Corresponding author.
Peer review under responsibility of Egyptian Society of Radiology and
Nuclear Medicine.
http://dx.doi.org/10.1016/j.ejrnm.2014.11.006
0378-603X  2014 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V. All rights reservGamal Niazi, Lobna Habib *Radiodiagnosis Department, Faculty of Medicine, Ain Shams University, Cairo, EgyptReceived 11 September 2014; accepted 5 November 2014




interventionsAbstract Purpose: To evaluate the effectiveness of the percutaneous ultrasound guided peri-ten-
dinous injection in improving or treating non-calciﬁc tendinopathy.
Patients and methods: Between January 2012 and March 2014, 25 patients with non calciﬁc tend-
inosis were treated by ultrasound guided corticosteroid injection. All patients underwent pre-treat-
ment diagnostic ultrasound, as well as assessment of the pain and disability of the affected area
through a self-answered questionnaire. Reevaluation of the ultrasound changes and clinical
response as regard the pain and disability score on regular follow up visits, were done at the 1st,
3rd and 6th month posttreatment.
Results: According to the results of this study, there was statistically marked reduction in patients
pain and disability score, with reduction of the mean pain score from maximum 3 points pre-treat-
ment to 0.5 post-treatment, and mean disability score form 1.5 point pre-treatment to 0 point at the
6th month follow up visit. The clinical success rate was 87%, with a technical success rate of 100%.
Conclusion: Ultrasound is a non invasive imaging technique that allows real time guidance for
interventional therapy of non-calciﬁc tendinopathy improving the result of peri-tendinous cortico-
steroid injection.
 2014 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier
B.V. All rights reserved.1. Introduction
Tendinopathy (often called tendinitis or tendinosis) is the most
common tendon disorder. It is characterized by activity related
pain, focal tenderness, and decreased range of movement in the
affected area. Tendinopathy can occur in almost any tendon,common examples include supraspinatus tendinitis, Achilles
tendinitis, patellar tendinitis and tennis elbow (1).
Tendinopathy is not characterized by an inﬂammatory
response, but rather inﬁltration of ﬁbroblasts and vessels, with
an ensuing chronic cycle of tendon degeneration and repair
resulting in a weakened tendon. These changes have been
shown to appear as hypoechoic areas on ultrasonography (2).
Conventional non-surgical treatment options include rela-
tive rest, cryotherapy, non-steroidal anti-inﬂammatory medi-
cations, physical therapy, and biomechanical devices.ed.
Table 1 Pain and disability score questionnaire.
Pain and disability score
Pain score 0 = no pain
1 = pain with forced active movement
2 = pain with simple active movement
3 = pain with passive movement
4 = pain at rest
5 = pain at rest and during sleep
Disability score 0 = intact full movement range
1 = near full movement range
2 = partial movement
3 = slight movement
4 = no movement
Fig. 1 Ultrasound evaluation of distal patellar tendon in
transverse (A) and longitudinal (B) view, revealed focal tendinosis
(arrow) appearing as a focal area of loss of ﬁbrillar pattern.
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ment option in those cases in which conservative treatment
had failed (3).
Reported surgical success rates have been variable, with
undesirable complication rates and prolonged recovery. In
an effort to shorten recovery and reduce morbidity, less inva-
sive approaches to the treatment of chronic tendon injuries
have been studied and shown to be effective (4).
With its associated technological improvements and associ-
ated lack of ionizing radiation, ultrasound (US) imaging is ideal
for guiding most musculoskeletal interventional procedures.
Unlike other imaging modalities, US has a unique advantage
in that it can visualize soft tissues, bony landmarks, and the nee-
dle using real-time scanning, allowing dynamic visualization. In
addition, there are no known contraindications to US (5).
Peri-tendinous injection of anesthetic and short acting cor-
ticosteroid is an effective means to treat tenosynovitis. Ultra-
sound guided injections have been shown to be an effective
mean to ensure correct localization of therapeutic agents (6).
The aim of this study is to evaluate the effectiveness of per-
cutaneous ultrasound guided injection in improving or treating
non calciﬁc tendinopathy.
2. Patients and methods
2.1. Patients
From January 2012 to March 2014, twenty-ﬁve patients with
non-calciﬁc tendinopathies identiﬁed based on clinical and
radiological evaluation, were prospectively treated with ultra-
sound guided peri-tendinous injections.
Patients were 12 males, 13 females, with age ranging from
20 to 55 years old (mean = 37.5).
Lesions were located in the biceps tendon (n= 9) (36%),
supra-spinatus tendon (n= 5) (20%), patellar tendon
(n= 3) (12%), Achilles tendon (n= 3) (12%), extensor ten-
don of the ﬁngers (n= 2) (8%), De Quervain tenosynovitis
(n= 2) (8%), and common extensor tendon of the elbow (ten-
nis elbow) (n= 1) (4%).
The patients included in our study were selected with the
following inclusion criteria:
1) Patients complaining of clinical manifestations sugges-
tive of tendinopathy as pain, focal tenderness, and
reduced range of movement of the affected muscle.
2) Symptoms of more than 6 months duration.
3) Failed conservative treatment over 6 months.
Patients excluded from our study, were those showing the
following exclusion criteria:
1) Radiological ﬁndings of tendon tear.
2) Patients with symptoms less than 6 months.
3) Patients who showed successful response to conservative
treatment.
2.2. Pretreatment patient assessment
A prospective evaluation was performed by using a pain and
disability score (PADS) questionnaire modiﬁed from theShoulder Pain and Disability Index (SPADI) questionnaire
(7). It is a self-administered score designed to measure the
response to treatment in time. It consists of 11 items divided
into two subcategories reﬂecting the pain (6 items) and disabil-
ity (5 items) associated with tendinopathy (Table 1). The ques-
tionnaire required 1 min to complete. This questionnaire was
ﬁlled out by the patient before the procedure and at regular
follow up at 1, 3 and 6 month after treatment.
The range of movement of the joint affected by the tendon
pathology is also evaluated, pre-treatment and on the follow
up visits, this helps to assess the degree of improvement in
the disability. It varies according to the affected joint e.g.
biceps tenosynovitis affects the shoulder ﬂexion, supraspinatus
tendinosis affects the full (150) shoulder abduction and
Achilles tendinosis affects the ankle planter ﬂexion.
The time of consultation from the onset of symptoms
varied between 6 months to as long as 1.5 year (the mean time
was 12 months). For patients with multiple joint related pains,
only the most symptomatic site was percutaneously treated
and included in our study.
A diagnostic preliminary US examination of each patient
was performed. The tendon was examined ﬁrst in a neutral
position and then during activity. All tendons were assessed
for presence of focal tendinosis, tendon effusion, increased vas-
cularity by power Doppler evaluation, and presence or absence
of tendon tear (Fig. 1).
Fig. 4 US guided peri-tendinous injection of Achilles tendinitis
with the patient lying in a prone position.
Ultrasound guided peri-tendinous injection in the treatment of non-calciﬁc tendinopathy 732.3. Ultrasound guided peri-tendinous injection technique
The procedure was explained to the patients in detail, then a
written consent was obtained, and after that the patient was
prepared for the percutaneous procedure.
During the procedure in general, the patient was seated
with the affected tendon best visualized, for most shoulder
cases, the patients were sitting on a rotating stool, for wrist
and elbow, the patients were sitting with the joint resting on
a straight table and for Achilles tendon, the patients were lay-
ing on the table in prone position (Figs. 2–4). A supine posi-
tion was favored for patients with history of vagal reaction
during any previous injections.
The procedure was performed by using sterile technique
and surgical gloves, where a pencil mark was placed on theFig. 2 Peri-tendinous injection of a case of De Quervain’s
tenosynovitis.
Fig. 3 Peri-tendinous injection of a case of tennis elbow.skin for localization. Then the skin was cleaned and antisepti-
cally draped using betadine. Also the transducer head was
cleaned and antiseptically draped.
After identifying and localizing the focal tendinosis by US,
and with relation to the clinical pain. Injection of the mixture
into the peritendinous area was done under constant US mon-
itoring, by using a 1.5-inch (3 cm) 25-gauge needle (Fig. 5).
The mixture used in all cases was short acting corticosteroid
(40 mg methylprednisolone acetate (Depo-Medrol) mixed with
Local anesthesia (2% Lidocaine hydrochloride (Dibucaine) in
a ratio of 1:2 or sometimes 1:3.
The average dose used was ranging from 2 ml in cases of De
Quervain’s and extensor digitorum tenosynovitis, up to 3 ml as
in cases of patellar and Achilles tendinosis.
In all cases, 2 sessions of injection with 2 weeks interval was
done and the clinical response as regard the pain was the main
parameter of continuation for the 2nd session and follow up.
In 3 cases a 3rd session of injection was done (2 cases showed
relapse of increasing pain score on the follow up visit at the 3rd
month, and one case who showed pre-treatment pain score of 4
(pain at rest) interfering with his daily activity, showed mild
pain reduction on the 1st month follow up.
In all cases, care was done to avoid intra-tendinous injec-
tion to avoid complicated tendon rupture, as after introducing
the needle, slow withdrawal was done with gentile injection, till
sudden release of resistance occurred.
Repeated insertion and withdrawal were done until cover-
age of the lesion with the injected material was accomplished.Fig. 5 The needle tip is seen in paratendinon (black arrow) with
injected therapy in paratendinon (white arrow head).





























74 G. Niazi, L. HabibAll patients experienced total disappearance of pain immedi-
ately within few minutes after injection.
Following the maneuver, patients were discharged with a
hand-written prescription for total rest of injected site for at
least 24 h before regaining normal activity, with no oral non
steroidal anti-inﬂammatory drugs prescribed along the course
of the treatment.
No technical failures occurred from the inability to localize
the symptomatic tendinopathy.
All interventions performed were free of any immediate
complications, except for 1 case who showed vasovagal synco-
pal attack during needle insertion; this was treated by laying
down the patient and elevating her legs. It lasted for few sec-
onds, after which the procedure continued with no problems.
2.4. Aftercare and follow up
Patients were reevaluated at regular follow-up visits (1, 3 and
6 month after the procedure). At each visit, they reﬁlled the
pain and disability score questionnaire. Also underwent a stan-
dard US examination which depicted the changes in echogenic-
ity, tendon thickness and calciﬁcation if present.
Statistical analysis was performed, that analyzed the differ-
ence in the pain and disability scores during the follow up visit.
3. Results
One patient (a woman of age, 33 years old with right biceps
tenosynovitis) had to be excluded from the study because fol-
low-up was missing and so medical records were incomplete.
Therefore, the clinical success and outcome was evaluated in
24 cases.
In our study, we considered the ability to enter the tendon
sheath and deliver the injected material in the peri-tendinous
area as a technical success.
Also we considered that complete or marked relief of
patients’ symptoms without the use of oral anti-inﬂammatory
drugs or physical therapy within the ﬁrst 6 months after the
procedure as a clinical success.
3.1. Pre and post treatment pain and disability score changes
The Mean pre-treatment pain score was 3 in 13 cases (54.2%)
with a maximum score of 4 seen in one case (4.2%) and a min-
imum score of 2 seen in 10 cases (41.6%).
The mean pre-treatment disability score was 1.5 with a
score of 2 seen in 13 cases (54.2), a maximum score of 3 seen
in one case (4.2%) and a minimum score of 0 seen in 10 cases
(41.6%) (Table 2).
15 patients out of 24 (62.5%) showed total disappearance
of their pain over 6 months post injection.
6 patients out of 24 (25%) showed marked reduction in
their pain scores with the most signiﬁcant reduction noted at
the end of the 6th month.
1 patient (4.2%) had not responded well regarding the pain
score. This patient (female, 44 years old) had right biceps teno-
synovitis; she was a known case of uncontrolled SLE.
2 patients (8.3%) showed an increase in their pain score
mainly after 1 month of injection, these patients developed
complicated intra-substance tendon tear diagnosed on the fol-
low up US examination (Table 3 and Fig. 6).The mean pain score for the patients has been reduced dur-
ing the ﬁrst 6 month post injections from 3 pre-treatment to
2.5 at the end of the 1st month, 1.5 at the end of the 3rd
month, and 0.5 at the end of 6th month with a mean value
of 2.5 points pain reduction (Fig. 7).
20 patients out of 24 (83.3%) showed total regain of full
joint movement over 6 months post injection, with 6 cases
(25%) showing full movement after 1st month, 9 cases
(37.5%) showing full movement after 3rd month and 5 cases
(20.8%) showing full movement after 6th month.
1 patient out of 24 (4.2%) showed no disability from the
start with full joint movement.
1 patient (4.2%) had no reduction in his disability score
which showed no change on follow up. It was the same female
patient with right biceps tenosynovitis.
2 patients (8.3%) showed complicated intra-substance tear
with no change in their disability score after 1st month (Table 4
and Fig. 8).
The mean disability score for the patients had been reduced
during the ﬁrst 6 month post injection from 1.5 pre-treatment
to 1 at the end of the 1st month, 0.5 at the end of the 3rd
month, and 0 at the end of 6th month with a mean value of
1.5 points disability reduction (Fig. 9).
3.2. Post treatment ultrasound changes
This was assessed by US examination performed regularly on
the follow up visits at 1st, 3rd and 6th month post-procedure.
We considered the ultrasound ﬁnding at the 6th month as the
net result ﬁnding. These results varied between total disappear-
ance of tendinopathy in 14 cases out of 24 (58.3%), partial
regaining of the normal ﬁbrillar pattern of the tendon in 4
cases out of 24 (16.7%) and no changes at all in 6 cases out
Table 3 Individual post-treatment pain score.
Patients Pre-treatment
pain score
Pain score at 1 month
post-treatment
Pain score at 3 months
post-treatment
Pain score at 6 months
post-treatment
1 3 1 0 0
2 2 1 0 0
3 3 1 0 0
4 3 2 1 0
5 3 2 1 0
6 3 2 3 3
7 2 1 0 0
8 3 2 1 1
9 3 2 1 0
10 2 1 0 0
11 2 1 0 0
12 3 4 Complicated tear
13 3 2 1 1
14 2 1 1 1
15 2 1 0 0
16 3 2 3 1
17 2 1 1 0
18 4 3 2 1
19 2 1 0 0
20 3 2 1 0
21 2 1 0 0
22 3 2 1 1
23 2 1 0 0
24 3 3 Complicated tear
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disability absence, and 2 cases developed complicated intra-
substance tendon tear (Fig. 10).
3.3. Clinical success rate (Table 5)
15 patients out of 24 (62%), showed total disappearance of
their pain and disability over the ﬁrst 6 month post-
treatment.
6 patients out of 24 (25%), showed marked reduction in
their pain and disability.
Therefore, the clinical success rate was estimated to be
87%.Fig. 6 Individual post-treatment pain score compared to pre-
treatment pain score.With technical success rate 100%, the total success rate was
87%.
The previous table shows that there was no statistically sig-
niﬁcant difference between the clinical and sonographic
results with p-value >0.05 (Fig. 11).
3.4. Complications
One minor complication occurred which was a vasovagal
syncope with needle insertion. That attack remained for few
seconds, after it the procedure continued with no problems.
Two major complications occurred, two patients (a male
patient with right supra-spinatus tendinosis and a female
patient with right biceps tenosynovitis) developed partialFig. 7 Post-treatment mean pain score compared to pre-treat-
ment pain score.
Fig. 8 Individual post-treatment disability score compared to
pre-treatment disability score.
Fig. 9 Post-treatment mean disability score compared to pre-
treatment disability score.
Fig. 10 Follow up ultrasound examination revealed disappear-
ance of the focal Achilles tendinos.
Table 4 Individual post-treatment disability score.
Patients Pre-treatment
disability score
Disability score at 1 month
post-treatment
Disability score at 3 months
post-treatment
Disability score at 6 months
post-treatment
1 2 1 0 0
2 0 0 0 0
3 2 1 0 0
4 1 1 0 0
5 1 1 1 0
6 2 2 2 2
7 1 0 0 0
8 2 2 1 0
9 2 1 0 0
10 1 1 0 0
11 1 1 0 0
12 2 2 Complicated tear
13 2 1 1 0
14 1 0 0 0
15 1 1 0 0
16 2 2 1 0
17 1 1 0 0
18 3 2 1 0
19 1 0 0 0
20 2 1 0 0
21 1 0 0 0
22 2 1 1 0
23 1 0 0 0
24 3 3 Complicated tear
76 G. Niazi, L. Habibtendon tear after the injection. This was diagnosed by US
examination in the ﬁrst follow up visit after the patient com-
plained of worsened pain. They were treated conservatively
with oral medications.
4. Discussion
Ultrasound is a technique that has gained widespread accep-
tance for musculoskeletal imaging and guiding interventions.
This noninvasive, non ionizing imaging technique allows con-
tinuous monitoring of the needle position, which facilitates the













Fig. 11 Comparison between the results of clinical and sono-
graphic ﬁndings.
Table 5 Comparison between the results of clinical and sonographic ﬁndings.
Chi-square test Sonographic Clinically
P-value X2 % No. % No.
0.459 0.547 75 18 87.5 21 Improved
25 6 12.5 3 Not improved
100 24 100 24 Total
P> 0.05: non signiﬁcant; P< 0.05: signiﬁcant; P< 0.01: highly signiﬁcant.
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remarkable paucity of controlled data to support their efﬁcacy.
That is because the randomized controlled trials were scarce
and their interpretation was frequently hindered by methodo-
logical issues, such as poor deﬁnition of cases, inclusion of het-
erogeneous study populations, small sample sizes, unsuitable
outcome measures, short term follow up, inadequate blinding
and lack of true placebo (9).
Most of the studies regarding the role of steroid injection in
tendinopathy showed that they are well tolerated and more
effective for tendinosis in the short-term than other injection
treatment, with lack of beneﬁt at long term therapy (10,11).
In a relative recent meta-analysis study, by Coombes et al., a
trial to compare data from many other studies to determine
the best use of injections for tendon problems. They showed
that corticosteroid injections reduced pain in the short term
compared with other interventions, but this effect was reversed
at intermediate and long terms (10).
During our study, 21out of 24 patients showed either total
or marked reduction of their pain and disability, 2 of them
showed recurrence of their pain and disability in less than
3 month post-injections. This clinical improvement was
achieved and continued for the 6 months follow up period.
So we suggest that steroid injection is effective in both short
and intermediate term of treatment, rather than short-term
only. It’s effect as long-term therapy (more than 6 months)
was beyond the scope of the study goal.
Evaluation of its efﬁcacy may be also hampered by the
accuracy of injection, as even in a specialist’s hands, up to
70% of injections may be misplaced. That is why the use of
ultrasonography as guidance for injection improves the efﬁ-
cacy (9).
Up till now few non sufﬁcient studies have been applied to
verify the role of ultrasound as image guidance in improving
the result of the injection therapy, however all these studiesrecommended its use, as they proved that it is more accurate
than the blind method. Till our update knowledge, very few
studies compared the efﬁcacy of cortisone injection in tendin-
opathy by both blind and ultrasound guided methods (8,12).
Lee et al. reported that ultrasound guided injection method
in trigger ﬁnger disease is more accurate and safer than the
blind method, they injected dye in 40 ﬁngers from 5 cadaveric
hands, then determined the dye location through dissection.
They reported that the dye was seen in the tendon sheath (opti-
mal site) in 70% of the 20 ﬁngers injected by ultrasound guid-
ance with 0% dye detection in tendon proper, compared to
only 15% in optimal site using blind methods with 30% dye
detection in the tendon proper (13).
In our study, we unfortunately did not make a comparative
study, comparing the result of injection under ultrasound guid-
ance vs. the blind method; however we depended on the clini-
cal response of the patients as indicator of effectiveness of
ultrasound guidance, and compared the clinical success to
other studies that involved injection by the blind method.
In our study, the technical success rate was 100%, and with
the clinical success rate of 87%, gave a 87% total success rate,
which is considered higher than reported by previous studies
that concerned the cortisone injection. This can be explained
by the fact that all these studies used blind method of injection,
which has proven to be less effective than image guided meth-
ods (14,15).
In our study, regarding the post-treatment sonographic ﬁnd-
ings, about 58% showed total disappearance of tendinopathy
within 6 months post-injection, and only 17% showed partial
improvement, giving an overall sonographic improvement of
about 75% of cases with only 25% showing no sonographic
changes. In correlation with our clinical success rate of 87%,
there was no signiﬁcant difference between the clinical improve-
ment and sonographic sign of improvement according to chi-
square test with P value of 0.459, which increased the value of
the success of injection.
It is believed that the patient’s response to previous injec-
tion is important in deciding whether and when to precede
with reinjection, as according to Cardone and Tallia, most
patients, if they are going to respond, will respond after the
ﬁrst injection. They also recommended that if therapeutic
effect is achieved, a maximum of four injections per year is rec-
ommended, fearing of that repeated use of corticosteroid prep-
arations may accelerate tendon weakness (16). In our study the
number of injections used for our patients ranged from 2 to
maximum 3 injections, depending on the degree of the clinical
improvement (according to self-answered questionnaire) and
recurrence of the pain in the follow up visits.
In spite of manufacturers of corticosteroid advising against
mixing it with Lidocaine, because of the risk of clumping and
precipitation of steroid crystals, most rheumatologist and
78 G. Niazi, L. Habibphysiotherapists mix it with local anesthesia. They believe that
this mixing, provides temporary analgesia, conﬁrms the deliv-
ery of medication to the appropriate target, and dilutes the
crystalline suspension, so that it is better diffused within the
injected region. We have never experienced this mixing as a
major problem.
Many studies (10,11,16,17), suggested adequate time
between injections, generally a minimum of four to six weeks,
however in our study the time interval was about 2 weeks. In
all previous studies, blind method of injection was done that
carries the risk of tendon injury, mainly due to lack of direct
visualization of needle position, that is avoided in ultrasound
guided methods. So waiting time to re-analyze possible compli-
cations is minimized in our study. Also in our study, we found
that this time interval is appropriate for maintaining a relative
adequate amount of the therapy for a relative longer period to
achieve more improvement and healing of the affected tendon.
In our study, 2 patients developed tendon tear. However, in
these patients, the tear occurred within the ﬁrst 2 weeks after
ﬁrst injection. We believe that it is not a result of corticosteroid
injection, but from a pre-treatment misdiagnosis, as the inci-
dence of tendon ruptures with steroid injection is rare, with
overall adverse effect incidence of about 5.8% as reported in
a relative recent study by Brinks et al. (18).
Also tendon tear as a complication of steroid injection was
categorized by the WHO, as a dose dependant side effect.
Several other injection therapies have been described to
treat tendinosis other than cortisone injections, and they carry
the future for more effective and safer treatment. Further stud-
ies for their efﬁcacy are recommended. The injection of autol-
ogous blood, which contains ﬁbroblast growth factors, has
been used successfully in treatment of refractory medial and
lateral epicondylitis of the elbow (19).
Prolotherapy is another treatment option that has shown
promising results. It is a technique in which injection of an irri-
tant solution incites a local inﬂammatory response, which, in
turn, induces ﬁbroblast proliferation and collagen synthesis.
Hyper-osmolar dextrose is considered the best substance, as
it has an excellent safety proﬁle and is inexpensive. In a recent
study by Carayannopoulos et al., which compared the efﬁcacy
of prolotherapy versus corticosteroid injection for the treat-
ment of chronic lateral epicondylitis, there was a signiﬁcant
higher success rate for prolotherapy than for corticosteroid
(20).
A newer injection treatment for tendinosis is gaining popu-
larity, the platelet rich plasma (PRP) injections. While this
treatment offers exciting hope, it is still relatively a newer tech-
nique with little evidence reviewed studies to back up its use
and efﬁcacy. However it is believed that platelet rich plasma
injection was superior to corticosteroid injection in relieving
pain for lateral epicondylalgia in the long term (10).
In conclusion, Corticosteroid injection is a relatively safe
and effective therapy in cases of non-calciﬁc tendinopathy
for short and intermediate term treatment. It is more effective
and safer by ultrasound guidance rather than the blind method
that depends on doctor expertise.5. Conﬂicts of interest
None declared.
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